Heart failure and respiratory tract infection: Cause and consequence of acute decompensation?

European Journal of Heart FailureEarly View Invited Editorial Heart failure and respiratory tract infection: Cause and consequence of acute decompensation? Bettina Heidecker, Corresponding Author Bettina Heidecker [email protected] orcid.org/0000-0002-3811-7920 Deutsches Herzzentrum der Charite, Universitätsmedizin Berlin, Berlin, Germany Berlin Institute of Health (BIH) at Charité, Berlin, Germany Corresponding author. Deutsches Herzzentrum der Charité, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany. Tel: +49 30 450513638, Email: [email protected]Search for more papers by this authorMatteo Pagnesi, Matteo Pagnesi Institute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, ItalySearch for more papers by this authorThomas F. Lüscher, Thomas F. Lüscher Cardiac Unit, Royal Brompton and Harefield Hospitals, London, UK King's College, Cardiovascular Academic Group, London, UK Imperial College, National Heart and Lung Institute, London, UK Center for Molecular Cardiology, University of Zurich, Zurich, SwitzerlandSearch for more papers by this author Bettina Heidecker, Corresponding Author Bettina Heidecker [email protected] orcid.org/0000-0002-3811-7920 Deutsches Herzzentrum der Charite, Universitätsmedizin Berlin, Berlin, Germany Berlin Institute of Health (BIH) at Charité, Berlin, Germany Corresponding author. Deutsches Herzzentrum der Charité, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany. Tel: +49 30 450513638, Email: [email protected]Search for more papers by this authorMatteo Pagnesi, Matteo Pagnesi Institute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, ItalySearch for more papers by this authorThomas F. Lüscher, Thomas F. Lüscher Cardiac Unit, Royal Brompton and Harefield Hospitals, London, UK King's College, Cardiovascular Academic Group, London, UK Imperial College, National Heart and Lung Institute, London, UK Center for Molecular Cardiology, University of Zurich, Zurich, SwitzerlandSearch for more papers by this author First published: 12 April 2024 https://doi.org/10.1002/ejhf.3209 The opinions expressed in this article are not necessarily those of the Editors of the European Journal of Heart Failure or of the European Society of Cardiology. doi: 10.1002/ejhf.3180. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: A comprehensive and updated review of epidemiology. Cardiovasc Res 2023; 118: 3272–3287. https://doi.org/10.1093/cvr/cvac013 10.1093/cvr/cvac013 PubMedWeb of Science®Google Scholar 2Savarese G, Stolfo D, Sinagra G, Lund LH. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol 2022; 19: 100–116. https://doi.org/10.1038/s41569-021-00605-5 10.1038/s41569-021-00605-5 PubMedWeb of Science®Google Scholar 3McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022; 24: 4–131. https://doi.org/10.1002/ejhf.2333 10.1002/ejhf.2333 PubMedWeb of Science®Google Scholar 4Shen L, Jhund PS, Anand IS, Bhatt AS, Desai AS, Maggioni AP, et al. Incidence and outcomes of pneumonia in patients with heart failure. J Am Coll Cardiol 2021; 77: 1961–1973. https://doi.org/10.1016/j.jacc.2021.03.001 10.1016/j.jacc.2021.03.001 PubMedWeb of Science®Google Scholar 5Bezati S, Velliou M, Ventoulis I, Simitsis P, Parissis J, Polyzogopoulou E. Infection as an under-recognized precipitant of acute heart failure: Prognostic and therapeutic implications. Heart Fail Rev 2023; 28: 893–904. https://doi.org/10.1007/s10741-023-10303-8 10.1007/s10741-023-10303-8 CASPubMedWeb of Science®Google Scholar 6Kobayashi M, Voors AA, Girerd N, Billotte M, Anker SD, Cleland JG, et al. Heart failure etiologies and clinical factors precipitating for worsening heart failure: Findings from BIOSTAT-CHF. Eur J Intern Med 2020; 71: 62–69. https://doi.org/10.1016/j.ejim.2019.10.017 10.1016/j.ejim.2019.10.017 PubMedWeb of Science®Google Scholar 7Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al.; OPTIMIZE-HF Investigators and Hospitals. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: Findings from OPTIMIZE-HF. Arch Intern Med 2008; 168: 847–854. https://doi.org/10.1001/archinte.168.8.847 10.1001/archinte.168.8.847 PubMedWeb of Science®Google Scholar 8Panhwar MS, Kalra A, Gupta T, Kolte D, Khera S, Bhatt DL, et al. Effect of influenza on outcomes in patients with heart failure. JACC Heart Fail 2019; 7: 112–117. https://doi.org/10.1016/j.jchf.2018.10.011 10.1016/j.jchf.2018.10.011 PubMedWeb of Science®Google Scholar 9Ferreira JP, Zannad F, Packer M, Filippatos G, Pocock SJ, Vasques-Nóvoa F, et al. Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR-Preserved analysis. Eur J Heart Fail. https://doi.org/10.1002/ejhf.3180 Published online ahead of print 04/03/24. 10.1002/ejhf.3180 Web of Science®Google Scholar 10Chen CY, Lee CH, Lin HW, Lin SH, Li YH. Impact of infection-related admission in patients with heart failure: A 10 years national cohort study. Sci Rep 2023; 13: 6941. https://doi.org/10.1038/s41598-023-34028-8 10.1038/s41598-023-34028-8 CASPubMedWeb of Science®Google Scholar 11Girerd N, Chapet N, Roubille C, Roncalli J, Salvat M, Mouquet F, et al. Vaccination for respiratory infections in patients with heart failure. J Clin Med 2021; 10:4311. https://doi.org/10.3390/jcm10194311 10.3390/jcm10194311 CASPubMedGoogle Scholar 12Bhatt AS, Kosiborod MN, Claggett BL, Miao ZM, Vaduganathan M, Lam CSP, et al. Impact of COVID-19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial. Eur J Heart Fail 2023; 25: 2177–2188. https://doi.org/10.1002/ejhf.3043 10.1002/ejhf.3043 CASPubMedGoogle Scholar 13 RECOVERY Collaborative Group. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet Diabetes Endocrinol 2023; 11: 905–914. https://doi.org/10.1016/S2213-8587(23)00253-X 10.1016/S2213-8587(23)00253-X PubMedWeb of Science®Google Scholar 14Kosiborod MN, Esterline R, Furtado RHM, Oscarsson J, Gasparyan SB, Koch GG, et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2021; 9: 586–594. https://doi.org/10.1016/S2213-8587(21)00180-7 10.1016/S2213-8587(21)00180-7 CASPubMedWeb of Science®Google Scholar 15Li HL, Tse YK, Chandramouli C, Hon NWL, Cheung CL, Lam LY, et al. Sodium-glucose cotransporter 2 inhibitors and the risk of pneumonia and septic shock. J Clin Endocrinol Metab 2022; 107: 3442–3451. https://doi.org/10.1210/clinem/dgac558 10.1210/clinem/dgac558 PubMedWeb of Science®Google Scholar 16Vaduganathan M, Claggett BL, Jhund P, Miao ZM, de Boer RA, Lam CSP, et al. Dapagliflozin and all-cause hospitalizations in patients with heart failure with preserved ejection fraction. J Am Coll Cardiol 2023; 81: 1004–1006. https://doi.org/10.1016/j.jacc.2022.12.026 10.1016/j.jacc.2022.12.026 CASPubMedWeb of Science®Google Scholar 17Vardeny O, Desai AS, Jhund PS, Fang JC, Claggett B, de Boer RA, et al. Dapagliflozin and mode of death in heart failure with improved ejection fraction: A post hoc analysis of the DELIVER trial. JAMA Cardiol 2024; 9: 283–289. https://doi.org/10.1001/jamacardio.2023.5318 10.1001/jamacardio.2023.5318 PubMedGoogle Scholar 18Desai AS, Jhund PS, Claggett BL, Vaduganathan M, Miao ZM, Kondo T, et al. Effect of dapagliflozin on cause-specific mortality in patients with heart failure across the spectrum of ejection fraction: A participant-level pooled analysis of DAPA-HF and DELIVER. JAMA Cardiol 2022; 7: 1227–1234. https://doi.org/10.1001/jamacardio.2022.3736 10.1001/jamacardio.2022.3736 PubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation